Patent intelligence · US
US 6118001
Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
Patent details — US 6118001
- Jurisdiction
- US
- Status
- expired
- Grant date
- Sep 12, 2000
- Expiration
- Sep 7, 2020
- Applicant
- Darwin Discovery Limited
- Claims
- 17
- CPC classes
- A61P, A61P17/00, A61P19/00, A61P19/04
Quick answer
US 6118001 (Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity) is held by Darwin Discovery Limited. Status: expired. Granted Sep 12, 2000. Expires Sep 7, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Darwin Discovery Limited
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61P, A61P17/00, A61P19/00, A61P19/04, A61P27/14, A61P29/00
More from Darwin Discovery Limited
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 6118001?
US 6118001 (Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity) is held by Darwin Discovery Limited. Status: expired. Granted Sep 12, 2000. Expires Sep 7, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6118001?
Darwin Discovery Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 6118001 expire?
Our index shows an expiration date of Sep 7, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.